<code id='DAD26353FD'></code><style id='DAD26353FD'></style>
    • <acronym id='DAD26353FD'></acronym>
      <center id='DAD26353FD'><center id='DAD26353FD'><tfoot id='DAD26353FD'></tfoot></center><abbr id='DAD26353FD'><dir id='DAD26353FD'><tfoot id='DAD26353FD'></tfoot><noframes id='DAD26353FD'>

    • <optgroup id='DAD26353FD'><strike id='DAD26353FD'><sup id='DAD26353FD'></sup></strike><code id='DAD26353FD'></code></optgroup>
        1. <b id='DAD26353FD'><label id='DAD26353FD'><select id='DAD26353FD'><dt id='DAD26353FD'><span id='DAD26353FD'></span></dt></select></label></b><u id='DAD26353FD'></u>
          <i id='DAD26353FD'><strike id='DAD26353FD'><tt id='DAD26353FD'><pre id='DAD26353FD'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:comprehensive    Page View:594
          John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT
          John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

          LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

          But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

          advertisement

          The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          Publishing genetic code of viruses could cause disaster
          Publishing genetic code of viruses could cause disaster

          HealthworkersatalabinHongKongtestingforcoronavirusinMarch2022.KinCheung/APThewhollysyntheticmRNAvacc

          read more
          George Santos makes 1st court appearance after pleading not guilty to 13 counts
          George Santos makes 1st court appearance after pleading not guilty to 13 counts

          1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

          read more

          I learned firsthand about improving diversity in clinical trials

          Asthebiopharmaceuticalindustryplacesincreasedemphasisonimprovingthediversityofparticipantsinclinical